Contrarius Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Contrarius Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$36.8M	Buy	783,898 +98,182	+14%	+$4.98M	2.1%	17
2024 Q2	$37M	Buy	685,716 +19,716	+3%	+$1.14M	2.32%	17
2024 Q1	$45.4M	Buy	666,000 +483,073	+264%	+$34.6M	2.62%	15
2023 Q4	$11.5M	Sell	182,927 -37,808	-17%	-$2.09M	0.62%	30
2023 Q3	$10M	Sell	220,735 -8,960	-4%	-$463K	0.56%	34
2023 Q2	$12.9M	Buy	+229,695	New	+$13M	0.69%	30

Other funds holding CRSP

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Contrarius Investment Management's CRSP Position: Q3 2024 in Review

Contrarius Investment Management increased its CRISPR Therapeutics (CRSP) stake by 14% in Q3 2024, buying an estimated $4.98M and bringing the position to 783,898 shares worth $36.8M. The position accounts for 2.1% of the portfolio, ranked #17.

Contrarius Investment Management first reported a position in CRSP in Q2 2023 and has held it in 6 quarters since. The position peaked at $45.4M in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Contrarius Investment Management held 783,898 shares of CRISPR Therapeutics worth $36.8M as of Q3 2024.
Contrarius Investment Management bought 98,182 CRISPR Therapeutics shares in Q3 2024, an estimated $4.98M.
CRISPR Therapeutics made up 2.1% of Contrarius Investment Management's portfolio in Q3 2024, its #17 holding.
Contrarius Investment Management first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 6 quarters since.
Contrarius Investment Management's CRISPR Therapeutics position peaked at $45.4M in Q1 2024.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Contrarius Investment Management's 13F filing for Q3 2024, filed 8 Nov 2024.